Scholarlink

<p>Acute myeloid leukemia (AML) is a highly heterogeneous myeloid malignancy which can be classified by genetic aberrations. To evaluate the impact of the dynamin 2 mutation in AML, we systematically assessed the characteristics and prognostic of <i>DNM2</i> mutated patients in AML. In 912 AML patients, 20 somatic mutations in the <i>DNM2</i> gene were identified among the 18 <i>DNM2</i> mutated AML patients (2%). Of the mutation events, 60% (12/20) were in the dynamin central region of <i>DNM2</i>. <i>DNM2</i>mutations were preferentially occurred in AML with <i>CEBPA</i> mutation (11/18, 61.1%), or <i>RUNX1::RUNX1T1</i> fusion gene (6/18, 33.3%). <i>DNM2</i> mutations were associated with better overall survival (<i>P</i> = 0.028), event-free survival (<i>P</i> = 0.0093) and trends towards better relapse-free survival (<i>P</i> = 0.08), which seems potentially attribute to its coexisting with <i>CEBPA</i> mutation and <i>RUNX1::RUNX1T1</i> fusion gene. Our study demonstrated the clinical characteristics and the role of <i>DNM2</i> mutations in AML, which might facilitate understanding the pathogenesis of AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月21日

查看全文
  • Kunpeng Luo,
  • Jiayuan Chen,
  • Wenting Wang,
  • Yan Hui,
  • Shaowei Qiu,
  • Bingcheng Liu,
  • Yingchang Mi,
  • Jianxiang Wang,
  • Hui Wei

摘要

Acute myeloid leukemia (AML) is a highly heterogeneous myeloid malignancy which can be classified by genetic aberrations. To evaluate the impact of the dynamin 2 mutation in AML, we systematically assessed the characteristics and prognostic of DNM2 mutated patients in AML. In 912 AML patients, 20 somatic mutations in the DNM2 gene were identified among the 18 DNM2 mutated AML patients (2%). Of the mutation events, 60% (12/20) were in the dynamin central region of DNM2. DNM2mutations were preferentially occurred in AML with CEBPA mutation (11/18, 61.1%), or RUNX1::RUNX1T1 fusion gene (6/18, 33.3%). DNM2 mutations were associated with better overall survival (P = 0.028), event-free survival (P = 0.0093) and trends towards better relapse-free survival (P = 0.08), which seems potentially attribute to its coexisting with CEBPA mutation and RUNX1::RUNX1T1 fusion gene. Our study demonstrated the clinical characteristics and the role of DNM2 mutations in AML, which might facilitate understanding the pathogenesis of AML.